{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:36:18Z","timestamp":1790361378532,"version":"4.1.0"},"reference-count":107,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Cyclophilins are cellular peptidyl-prolyl isomerases that play an important role in viral infections, with demonstrated roles in the replication of hepatitis C virus (HCV) and other viruses in the Flaviviridae family, such as dengue virus (DENV) and yellow fever virus (YFV). Here, we discuss the roles of cyclophilins in HCV infection and provide a comprehensive overview of the mechanisms underlying the requirement for cyclophilins during HCV replication. Notably, cyclophilin inhibitor therapy has been demonstrated to be effective in reducing HCV replication in chronically infected patients. While the roles of cyclophilins are relatively well-understood for HCV infection, cyclophilins are more recently emerging as host factors for flavivirus infection as well, providing potential new therapeutic avenues for these viral infections which currently lack antiviral therapies. However, further studies are required to elucidate the roles of cyclophilins in flavivirus replication. Here, we review the current knowledge of the role of cyclophilins in HCV infection to provide a conceptual framework to understand how cyclophilins may contribute to other viral infections, such as DENV and YFV. Improved understanding of the roles of cyclophilins in viral infection may open perspectives for the development of cyclophilin inhibitors as effective antiviral therapeutics for HCV and related viruses.<\/jats:p>","DOI":"10.3390\/pathogens10070902","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T21:18:52Z","timestamp":1626643132000},"page":"902","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cyclophilins and Their Roles in Hepatitis C Virus and Flavivirus Infections: Perspectives for Novel Antiviral Approaches"],"prefix":"10.3390","volume":"10","author":[{"given":"Carla E.","family":"Gallardo-Flores","sequence":"first","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2474-1834","authenticated-orcid":false,"given":"Che C.","family":"Colpitts","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Fayek, S.A., Quintini, C., Chavin, K.D., and Marsh, C.L. (2016). The current state of liver transplantation in the United States: Perspective from American Society of Transplant Surgeons (ASTS) scientific studies committee and endorsed by ASTS council. Am. J. Transplant.","DOI":"10.1111\/ajt.14017"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Stanaway, J.D., Flaxman, A.D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., Abu-Raddad, L.J., Assadi, R., Bhala, N., and Cowie, B. (2016). The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013. Lancet.","DOI":"10.1016\/S0140-6736(16)30579-7"},{"key":"ref_4","unstructured":"World Health Organization (2021, June 30). Global Hepatitis Report. Available online: https:\/\/www.who.int\/publications\/i\/item\/global-hepatitis-report-2017."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1016\/S2214-109X(15)00156-4","article-title":"Disparity in market prices for hepatitis C virus direct-acting drugs","volume":"3","author":"Cohn","year":"2015","journal-title":"Lancet Glob. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/apt.16054","article-title":"Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes","volume":"52","author":"Fourati","year":"2020","journal-title":"Aliment. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4103\/jfmpc.jfmpc_943_19","article-title":"Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection\u2014A brief review of literature","volume":"9","author":"Bhatia","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Colpitts, C.C., and Baumert, T.F. (2016). Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure. Viruses, 8.","DOI":"10.3390\/v8080226"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Simmonds, P., Becher, P., Bukh, J., Gould, E.A., Meyers, G., Monath, T., Muerhoff, S., Pletnev, A., Rico-Hesse, R., and Smith, D.B. (2017). ICTV virus taxonomy profile: Flaviviridae. J. Gen. Virol.","DOI":"10.1099\/jgv.0.000672"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Colpitts, C.C., Tsai, P.L., and Zeisel, M.B. (2020). Hepatitis C virus entry: An intriguingly complex and highly regulated process. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062091"},{"key":"ref_12","unstructured":"Lin, C. (2006). HCV NS3-4A Serine Protease. Hepatitis C Viruses: Genomes and Molecular Biology, Horizon Bioscience."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1093\/emboj\/cdf414","article-title":"Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets","volume":"21","author":"McLauchlan","year":"2002","journal-title":"EMBO J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.20032","article-title":"Structural biology of hepatitis C virus","volume":"39","author":"Penin","year":"2004","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Romero-Brey, I., Merz, A., Chiramel, A., Lee, J.Y., Chlanda, P., Haselman, U., Santarella-Mellwig, R., Habermann, A., Hoppe, S., and Kallis, S. (2012). Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1003056"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Neufeldt, C.J., Joyce, M.A., Van Buuren, N., Levin, A., Kirkegaard, K., Gale, M., Tyrrell, D.L.J., and Wozniak, R.W. (2016). The hepatitis C virus-induced membranous web and associated nuclear transport machinery limit access of pattern recognition receptors to viral replication sites. PLoS Pathog.","DOI":"10.1371\/journal.ppat.1005428"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kim, C.W., and Chang, K.M. (2013). Hepatitis C virus: Virology and life cycle. Clin. Mol. Hepatol.","DOI":"10.3350\/cmh.2013.19.1.17"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tellinghuisen, T.L., Foss, K.L., and Treadaway, J. (2008). Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.1000032"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1128\/JVI.03170-13","article-title":"Involvement of hepatitis C virus NS5A hyperphosphorylation mediated by casein kinase I-alpha in infectious virus production","volume":"88","author":"Masaki","year":"2014","journal-title":"J. Virol."},{"key":"ref_20","first-page":"199","article-title":"Virion assembly and release","volume":"369","author":"Lindenbach","year":"2013","journal-title":"Hepat. C Virus"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Syed, G.H., Khan, M., Yang, S., and Siddiqui, A. (2017). Hepatitis C virus lipoviroparticles assemble in the endoplasmic reticulum (ER) and bud off from the ER to the Golgi compartment in COPII vesicles. J. Virol.","DOI":"10.1128\/JVI.00499-17"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Handschumacher, R.E., Harding, M.W., Rice, J., Drugge, R.J., and Speicher, D.W. (1984). Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science.","DOI":"10.1126\/science.6238408"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Borel, J.F., Feurer, C., Gubler, H.U., and St\u00e4helin, H. (1994). Biological effects of cyclosporin A: A new antilymphocytic agent. Agents Actions.","DOI":"10.1007\/BF01986686"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Clipstone, N.A., and Crabtree, G.R. (1992). Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature.","DOI":"10.1038\/357695a0"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Liu, J., Farmer, J.D., Lane, W.S., Friedman, J., Weissman, I., and Schreiber, S.L. (1991). Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell.","DOI":"10.1016\/0092-8674(91)90124-H"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.bbrc.2006.03.059","article-title":"Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811","volume":"343","author":"Goto","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1128\/AAC.00310-06","article-title":"NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon","volume":"50","author":"Ma","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Paeshuyse, J., Kaul, A., De Clercq, E., Rosenwirth, B., Dumont, J.M., Scalfaro, P., Bartenschlager, R., and Neyts, J. (2006). The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology.","DOI":"10.1002\/hep.21102"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/AAC.00660-09","article-title":"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro","volume":"54","author":"Hopkins","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12777","DOI":"10.1038\/ncomms12777","article-title":"Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities","volume":"7","author":"Colliandre","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9473","DOI":"10.1021\/acs.jmedchem.8b00802","article-title":"Discovery of a potent and orally bioavailable cyclophilin inhibitor derived from the sanglifehrin macrocycle","volume":"61","author":"Mackman","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Colpitts, C.C., Ridewood, S., Schneiderman, B., Warne, J., Tabata, K., Ng, C.F., Bartenschlager, R., Selwood, D.L., and Towers, G.J. (2020). Hepatitis C virus exploits cyclophilin a to evade PKR. eLife.","DOI":"10.7554\/eLife.52237.sa2"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Stamnes, M.A., Rutherford, S.L., and Zuker, C.S. (1992). Cyclophilins: A new family of proteins involved in intracellular folding. Trends Cell Biol.","DOI":"10.1016\/0962-8924(92)90200-7"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Davis, T.L., Walker, J.R., Campagna-Slater, V., Finerty, P.J., Finerty, P.J., Paramanathan, R., Bernstein, G., Mackenzie, F., Tempel, W., and Ouyang, H. (2010). Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases. PLoS Biol.","DOI":"10.1371\/journal.pbio.1000439"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kallen, J., Spitzfaden, C., Zurini, M.G.M., Wider, G., Widmer, H., W\u00fcthrich, K., and Walkinshaw, M.D. (1991). Structure of human cyclophilin and its binding site for cyclosporin A determined by X-ray crystallography and NMR spectroscopy. Nature.","DOI":"10.1038\/353276a0"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kumari, S., Roy, S., Singh, P., Singla-Pareek, S.L., and Pareek, A. (2013). Cyclophilins: Proteins in search of function. Plant. Signal. Behav.","DOI":"10.4161\/psb.22734"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1038\/cddis.2013.410","article-title":"Cyclophilin A: A key player for human disease","volume":"4","author":"Nigro","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Sherry, B., Yarlett, N., Strupp, A., and Cerami, A. (1992). Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc. Natl. Acad. Sci. USA.","DOI":"10.1073\/pnas.89.8.3511"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Spik, G., Haendler, B., Delmas, O., Mariller, C., Chamoux, M., Maes, P., Tartar, A., Montreuil, J., Stedman, K., and Kocher, H.P. (1991). A novel secreted cyclophilin-like protein (SCYLP). J. Biol. Chem.","DOI":"10.1016\/S0021-9258(18)99078-2"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Suzuki, J., Jin, Z.G., Meoli, D.F., Matoba, T., and Berk, B.C. (2006). Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ. Res.","DOI":"10.1161\/01.RES.0000216405.85080.a6"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature12769","article-title":"HIV-1 evades innate immune recognition through specific cofactor recruitment","volume":"503","author":"Rasaiyaah","year":"2013","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Qing, M., Yang, F., Zhang, B., Zou, G., Robida, J.M., Yuan, Z., Tang, H., and Shi, P.Y. (2009). Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob. Agents Chemother.","DOI":"10.1128\/AAC.00189-09"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1021\/acs.jproteome.6b00933","article-title":"Systems biology reveals NS4B-cyclophilin A interaction: A new target to inhibit YFV replication","volume":"16","author":"Vidotto","year":"2017","journal-title":"J. Proteome Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A screen of FDA-approved drugs for inhibitors of Zika virus infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.virol.2011.01.011","article-title":"Involvement of cyclophilin B in the replication of Japanese encephalitis virus","volume":"412","author":"Kambara","year":"2011","journal-title":"Virology"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Pfefferle, S., Sch\u00f6pf, J., K\u00f6gl, M., Friedel, C.C., M\u00fcller, M.A., Carbajo-Lozoya, J., Stellberger, T., von Dall\u2019Armi, E., Herzog, P., and Kallies, S.J.P.p. (2011). The SARS-coronavirus-host interactome: Identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002331"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virusres.2014.02.010","article-title":"Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir","volume":"184","author":"Malesevic","year":"2014","journal-title":"Virus Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1099\/vir.0.034983-0","article-title":"Cyclosporin A inhibits the replication of diverse coronaviruses","volume":"92","author":"Thiel","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.virol.2017.11.022","article-title":"Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture","volume":"517","author":"Beugeling","year":"2018","journal-title":"Virology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"104620","DOI":"10.1016\/j.antiviral.2019.104620","article-title":"Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication","volume":"173","author":"Zheng","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Sauerhering, L., Kupke, A., Meier, L., Dietzel, E., Hoppe, J., Gruber, A.D., Gattenloehner, S., Witte, B., Fink, L., and Hofmann, N. (2020). Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus via interferon-lambda in vitro and in mice. Eur. Respir. J., 56.","DOI":"10.1183\/13993003.01826-2019"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Softic, L., Brillet, R., Berry, F., Ahnou, N., Nevers, Q., Morin-Dewaele, M., Hamadat, S., Bruscella, P., Fourati, S., and Pawlotsky, J.M. (2020). Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor alisporivir (Debio 025). Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.00876-20"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/117739280700200017","article-title":"Cyclophilin and viruses: Cyclophilin as a cofactor for viral infection and possible anti-viral target","volume":"2","author":"Watashi","year":"2007","journal-title":"Drug Target. Insights"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., and Shimotohno, K. (2003). Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology.","DOI":"10.1053\/jhep.2003.50449"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bbrc.2003.11.080","article-title":"Specific inhibition of hepatitis C virus replication by cyclosporin A","volume":"313","author":"Nakagawa","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1128\/JVI.80.9.4510-4520.2006","article-title":"Diverse effects of cyclosporine on hepatitis C virus strain replication","volume":"80","author":"Ishii","year":"2006","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Inoue, K., Sekiyama, K., Yamada, M., Watanabe, T., Yasuda, H., and Yoshiba, M. (2003). Combined interferon \u03b12b and cyclosporin A in the treatment of chronic hepatitis C: Controlled trial. J. Gastroenterol.","DOI":"10.1007\/s00535-002-1104-5"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.transproceed.2004.11.041","article-title":"Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease","volume":"37","author":"Inoue","year":"2005","journal-title":"Transplant. Proc."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Stanciu, C., Trifan, A., Muzica, C., and Sfarti, C. (2019). Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opin. Pharmacother.","DOI":"10.1080\/14656566.2018.1560424"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.3390\/v4112558","article-title":"Cyclophilin inhibitors: An emerging class of therapeutics for the treatment of chronic hepatitis C infection","volume":"4","author":"Hopkins","year":"2012","journal-title":"Viruses"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Nakagawa, M., Sakamoto, N., Tanabe, Y., Koyama, T., Itsui, Y., Takeda, Y., Chen, C.H., Kakinuma, S., Oooka, S., and Maekawa, S. (2005). Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology.","DOI":"10.1053\/j.gastro.2005.06.031"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Watashi, K., Ishii, N., Hijikata, M., Inoue, D., Murata, T., Miyanari, Y., and Shimotohno, K. (2005). Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell.","DOI":"10.1016\/j.molcel.2005.05.014"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Yang, F., Robotham, J.M., Nelson, H.B., Irsigler, A., Kenworthy, R., and Tang, H. (2008). Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol.","DOI":"10.1128\/JVI.02614-07"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chatterji, U., Bobardt, M., Selvarajah, S., Yang, F., Tang, H., Sakamoto, N., Vuagniaux, G., Parkinson, T., and Gallay, P. (2009). The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem.","DOI":"10.1074\/jbc.M109.007625"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kaul, A., Stauffer, S., Berger, C., Pertel, T., Schmitt, J., Kallis, S., Lopez, M.Z., Lohmann, V., Luban, J., and Bartenschlager, R. (2009). Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog.","DOI":"10.1371\/annotation\/29dffb2a-5d37-4196-b166-b0b15bc2f3fd"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Fernandes, F., Poole, D.S., Hoover, S., Middleton, R., Andrei, A.C., Gerstner, J., and Striker, R. (2007). Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology.","DOI":"10.1002\/hep.21809"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Heck, J.A., Meng, X., and Frick, D.N. (2009). Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase. Biochem. Pharmacol.","DOI":"10.1016\/j.bcp.2008.12.019"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.bbagen.2012.08.017","article-title":"Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro","volume":"1820","author":"Weng","year":"2012","journal-title":"Biochim. Et Biophys. Acta-Gen. Subj."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Tellinghuisen, T.L., Foss, K.L., Treadaway, J.C., and Rice, C.M. (2008). Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J. Virol.","DOI":"10.1128\/JVI.00328-07"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Appel, N., Zayas, M., Miller, S., Krijnse-Locker, J., Schaller, T., Friebe, P., Kallis, S., Engel, U., and Bartenschlager, R. (2008). Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.1000035"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1074\/jbc.M809244200","article-title":"Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis\/trans isomerase activity of cyclophilins A and B","volume":"284","author":"Hanoulle","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Chatterji, U., Lim, P., Bobardt, M.D., Wieland, S., Cordek, D.G., Vuagniaux, G., Chisari, F., Cameron, C.E., Targett-Adams, P., and Parkinson, T. (2010). HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol.","DOI":"10.1016\/j.jhep.2010.01.041"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Foster, T.L., Gallay, P., Stonehouse, N.J., and Harris, M. (2011). Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J. Virol.","DOI":"10.1128\/JVI.00393-11"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1128\/JVI.06641-11","article-title":"A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility","volume":"86","author":"Grise","year":"2012","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Coelmont, L., Hanoulle, X., Chatterji, U., Berger, C., Snoeck, J., Bobardt, M., Lim, P., Vliegen, I., Paeshuyse, J., and Vuagniaux, G. (2010). DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013687"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Yang, F., Robotham, J.M., Grise, H., Frausto, S., Madan, V., Zayas, M., Bartenschlager, R., Robinson, M., Greenstein, A.E., and Nag, A. (2010). A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001118"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"12616","DOI":"10.1128\/JVI.01351-12","article-title":"Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors","volume":"86","author":"Nag","year":"2012","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Dujardin, M., Madan, V., Gandhi, N.S., Cantrelle, F.X., Launay, H., Huvent, I., Bartenschlager, R., Lippens, G., and Hanoulle, X. (2019). Cyclophilin A allows the allosteric regulation of a structural motif in the disordered domain 2 of NS5A and thereby fine-tunes HCV RNA replication. J. Biol. Chem.","DOI":"10.1074\/jbc.RA119.009537"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Rosnoblet, C., Fritzinger, B., Legrand, D., Launay, H.e., Wieruszeski, J.M., Lippens, G., and Hanoulle, X. (2012). Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A. J. Biol. Chem.","DOI":"10.1074\/jbc.M112.392209"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Ngure, M., Issur, M., Shkriabai, N., Liu, H.W., Cosa, G., Kvaratskhelia, M., and G\u00f6tte, M. (2016). Interactions of the disordered domain II of hepatitis C virus NS5A with cyclophilin A, NS5B, and viral RNA show extensive overlap. ACS Infect. Dis.","DOI":"10.1021\/acsinfecdis.6b00143"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1128\/JVI.02550-08","article-title":"Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex","volume":"83","author":"Liu","year":"2009","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Madan, V., Paul, D., Lohmann, V., and Bartenschlager, R. (2014). Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation. Gastroenterology.","DOI":"10.1053\/j.gastro.2014.01.055"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1128\/AAC.04958-14","article-title":"Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories","volume":"59","author":"Chatterji","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/hep.23281","article-title":"Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A","volume":"50","author":"Ciesek","year":"2009","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"20441","DOI":"10.1074\/jbc.M110.182436","article-title":"Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A","volume":"286","author":"Verdegem","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/1743-422X-8-329","article-title":"Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretion","volume":"8","author":"Anderson","year":"2011","journal-title":"Virol. J."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Daito, T., Watashi, K., Sluder, A., Ohashi, H., Nakajima, S., Borroto-Esoda, K., Fujita, T., and Wakita, T. (2014). Cyclophilin inhibitors reduce phosphorylation of RNA-dependent protein kinase to restore expression of IFN-stimulated genes in HCV-infected cells. Gastroenterology.","DOI":"10.1053\/j.gastro.2014.04.035"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874357901408010001","article-title":"Both cyclophilin inhibitors and direct-acting antivirals prevent PKR activation in HCV-infected cells","volume":"8","author":"Bobardt","year":"2014","journal-title":"Open Virol. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1073\/pnas.062055699","article-title":"Regulation of PKR and IRF-1 during hepatitis C virus RNA replication","volume":"99","author":"Pflugheber","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1128\/MCB.18.9.5208","article-title":"Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation","volume":"18","author":"Gale","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1128\/JVI.79.5.2689-2699.2005","article-title":"Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I","volume":"79","author":"Sumpter","year":"2005","journal-title":"J. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","article-title":"The continued threat of emerging flaviviruses","volume":"5","author":"Pierson","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(07)61687-0","article-title":"Dengue","volume":"370","author":"Halstead","year":"2007","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Bhatt, S., Gething, P.W., Brady, O.J., Messina, J.P., Farlow, A.W., Moyes, C.L., Drake, J.M., Brownstein, J.S., Hoen, A.G., and Sankoh, O. (2013). The global distribution and burden of dengue. Nature.","DOI":"10.1038\/nature12060"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.mcna.2008.07.004","article-title":"West Nile virus in the Americas","volume":"92","author":"Petersen","year":"2008","journal-title":"Med. Clin. N. Am."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"572681","DOI":"10.3389\/fcimb.2020.572681","article-title":"Antibody-dependent enhancement: A challenge for developing a safe dengue vaccine","volume":"10","author":"Shukla","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Chambers, T.J., Hahn, C.S., Galler, R., and Rice, C.M. (1990). Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol.","DOI":"10.1146\/annurev.mi.44.100190.003245"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Bonaldo, M.C., G\u00f3mez, M.M., Dos Santos, A.A.C., De Abreu, F.V.S., Ferreira-de-Brito, A., De Miranda, R.M., De Castro, M.G., and Louren\u00e7o-de-Oliveira, R. (2017). Genome analysis of yellow fever virus of the ongoing outbreak in brazil reveals polymorphisms. Mem. Inst. Oswaldo Cruz.","DOI":"10.1590\/0074-02760170134"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Sahili, E.A., and Lescar, J. (2017). Dengue virus non-structural protein 5. Viruses, 9.","DOI":"10.3390\/v9040091"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrmicro.2017.170","article-title":"Rewiring cellular networks by members of the Flaviviridae family","volume":"16","author":"Neufeldt","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Nevers, Q., Ruiz, I., Ahnou, N., Donati, F., Brillet, R., Softic, L., Chazal, M., Jouvenet, N., Fourati, S., and Baudesson, C. (2018). Characterization of the anti-hepatitis C virus activity of new nonpeptidic small-molecule cyclophilin inhibitors with the potential for broad anti-Flaviviridae activity. Antimicrob. Agents Chemother.","DOI":"10.1128\/AAC.00126-18"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Deviatkin, A.A., Kholodilov, I.S., Vakulenko, Y.A., Karganova, G.G., and Lukashev, A.N. (2020). Tick-borne encephalitis virus: An emerging ancient zoonosis?. Viruses, 12.","DOI":"10.3390\/v12020247"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Tambo, E., and El-Dessouky, A.G. (2018). Defeating re-emerging Alkhurma hemorrhagic fever virus outbreak in Saudi Arabia and worldwide. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006707"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/vbz.2017.2110","article-title":"Powassan virus: An emerging arbovirus of public health concern in North America","volume":"17","author":"Hermance","year":"2017","journal-title":"Vector-Borne Zoonotic Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1128\/AAC.01627-10","article-title":"Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family","volume":"55","author":"Gregory","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Bobardt, M., Hansson, M.J., Mayo, P., Ure, D., Foster, R., and Gallay, P. (2020). Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237236"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/7\/902\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:31:09Z","timestamp":1760164269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/7\/902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,17]]},"references-count":107,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["pathogens10070902"],"URL":"https:\/\/doi.org\/10.3390\/pathogens10070902","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,17]]}}}